X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Piramal Healthcare with Lupin Ltd - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

PIRAMAL ENTERPRISES vs LUPIN LTD - Comparison Results

PIRAMAL ENTERPRISES    Change

Piramal Enterprises has a presence in custom manufacturing, critical care OTC and financial services. To give a boost to its custom manufacturing operations, the company had acquired Avecia Pharmaceuticals, UK in 2005 and Pfizer's Morpeth facility in... More

LUPIN LTD 
   Change

Lupin is a leading pharmaceutical company with a strong presence in anti-infective, cardiovascular and asthma. Apart from having a strong domestic presence, the company markets its products in the regulated markets of the US and Europe and semi-regul... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    PIRAMAL ENTERPRISES LUPIN LTD PIRAMAL ENTERPRISES/
LUPIN LTD
 
P/E (TTM) x 8.7 163.6 5.3% View Chart
P/BV x 2.9 3.0 95.3% View Chart
Dividend Yield % 0.8 0.8 102.0%  

Financials

 PIRAMAL ENTERPRISES   LUPIN LTD
EQUITY SHARE DATA
    PIRAMAL ENTERPRISES
Mar-17
LUPIN LTD
Mar-17
PIRAMAL ENTERPRISES/
LUPIN LTD
5-Yr Chart
Click to enlarge
High Rs2,0951,750 119.7%   
Low Rs1,0251,384 74.1%   
Sales per share (Unadj.) Rs492.8387.4 127.2%  
Earnings per share (Unadj.) Rs72.656.6 128.1%  
Cash flow per share (Unadj.) Rs94.776.8 123.2%  
Dividends per share (Unadj.) Rs21.007.50 280.0%  
Dividend yield (eoy) %1.30.5 281.2%  
Book value per share (Unadj.) Rs862.5298.9 288.5%  
Shares outstanding (eoy) m172.56451.58 38.2%   
Bonus/Rights/Conversions -ESOPS-  
Price / Sales ratio x3.24.0 78.3%   
Avg P/E ratio x21.527.7 77.7%  
P/CF ratio (eoy) x16.520.4 80.8%  
Price / Book Value ratio x1.85.2 34.5%  
Dividend payout %28.913.2 218.6%   
Avg Mkt Cap Rs m269,194707,513 38.0%   
No. of employees `0004.016.8 23.9%   
Total wages/salary Rs m17,93928,495 63.0%   
Avg. sales/employee Rs Th21,190.310,418.3 203.4%   
Avg. wages/employee Rs Th4,470.11,697.0 263.4%   
Avg. net profit/employee Rs Th3,120.01,523.0 204.9%   
INCOME DATA
Net Sales Rs m85,037174,943 48.6%  
Other income Rs m2,3381,065 219.5%   
Total revenues Rs m87,374176,008 49.6%   
Gross profit Rs m34,99144,931 77.9%  
Depreciation Rs m3,8179,122 41.8%   
Interest Rs m20,3101,525 1,331.5%   
Profit before tax Rs m13,20235,349 37.3%   
Minority Interest Rs m1,699-72 -2,369.6%   
Prior Period Items Rs m083 0.0%   
Extraordinary Inc (Exp) Rs m-1000-   
Tax Rs m2,2819,785 23.3%   
Profit after tax Rs m12,52025,575 49.0%  
Gross profit margin %41.125.7 160.2%  
Effective tax rate %17.327.7 62.4%   
Net profit margin %14.714.6 100.7%  
BALANCE SHEET DATA
Current assets Rs m87,590119,542 73.3%   
Current liabilities Rs m185,57861,206 303.2%   
Net working cap to sales %-115.233.3 -345.6%  
Current ratio x0.52.0 24.2%  
Inventory Days Days3176 40.8%  
Debtors Days Days4890 52.9%  
Net fixed assets Rs m108,523131,660 82.4%   
Share capital Rs m345903 38.2%   
"Free" reserves Rs m148,481134,073 110.7%   
Net worth Rs m148,826134,976 110.3%   
Long term debt Rs m144,95756,478 256.7%   
Total assets Rs m482,394266,073 181.3%  
Interest coverage x1.724.2 6.8%   
Debt to equity ratio x1.00.4 232.8%  
Sales to assets ratio x0.20.7 26.8%   
Return on assets %6.810.2 66.8%  
Return on equity %8.418.9 44.4%  
Return on capital %12.019.3 62.0%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m15,00181,885 18.3%   
Fx outflow Rs m5,15021,506 23.9%   
Net fx Rs m9,85160,378 16.3%   
CASH FLOW
From Operations Rs m-100,39341,148 -244.0%  
From Investments Rs m-24,202-25,287 95.7%  
From Financial Activity Rs m135,7054,332 3,132.8%  
Net Cashflow Rs m11,11020,193 55.0%  

Share Holding

Indian Promoters % 52.9 46.6 113.5%  
Foreign collaborators % 0.0 0.2 -  
Indian inst/Mut Fund % 4.0 11.3 35.4%  
FIIs % 26.6 31.9 83.4%  
ADR/GDR % 0.0 0.0 -  
Free float % 16.5 10.1 163.4%  
Shareholders   93,274 98,259 94.9%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare PIRAMAL ENTERPRISES With:   BIOCON LTD  CADILA HEALTHCARE  SUVEN LIFE  PANACEA BIOTECH  WOCKHARDT LTD.  

Compare PIRAMAL ENTERPRISES With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Trade War Fears; Widening of Trade Deficit and Top Stocks in Action Today(Pre-Open)

Indian share markets trimmed their day's losses and ended flat on Friday amid weakness in their Asian peers, that wobbled on Friday as investors braced for US tariffs against China.

Related Views on News

PIRAMAL ENTERPRISES Announces Quarterly Results (4QFY18); Net Profit Up 1230.7%

May 30, 2018 | Updated on May 30, 2018

For the quarter ended March 2018, PIRAMAL ENTERPRISES has posted a net profit of Rs 39 bn (up 1230.7% YoY). Sales on the other hand came in at Rs 30 bn (up 21.5% YoY). Read on for a complete analysis of PIRAMAL ENTERPRISES's quarterly results.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Lupin: US Markets Drags down Revenues and Net Profits (Quarterly Results Update - Detailed)

Nov 2, 2017

Domestic markets registers robust growth in the quarter

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

More Views on News

Most Popular

After Vakrangee and Manpasand, More Auditors May Soon Resign. To Protect Your Wealth, Avoid these Stocks(The 5 Minute Wrapup)

Jun 8, 2018

The change in auditing regulations can bring a big change in corporate governance behaviour in the mid and small-cap space.

Should You Get out of Small Caps Now... Before the Fall Worsens(Profit Hunter)

Jun 6, 2018

An almost zero-loss strategy that works best when markets correct. Don't let the current volatility overwhelm you. Focus on the fundamentals and long term, and buy stocks where quality meets value.

Why Bank-Mergers Continue to Remain a Bad Idea(Vivek Kaul's Diary)

Jun 5, 2018

A newsreport suggests that the government plans to merge four public sector banks. We think it's a bad idea.

Has the Market Bottomed Out?(Sector Info)

Jun 11, 2018

The yield spread is an effective barometer that can indicate the direction the markets are headed.

Is Data Pointing Towards a Revival in the FMCG Sector?(Sector Info)

Jun 8, 2018

After several quarters of stress in the aftermath of demonetisation and the rollout of GST, this data is pointing towards revival in the India's rural FMCG industry.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

PIRAMAL ENTERPRISES SHARE PRICE


Jun 15, 2018 (Close)

TRACK PIRAMAL ENTERPRISES

  • Track your investment in PIRAMAL ENTERPRISES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON PIRAMAL ENTERPRISES

PIRAMAL ENTERPRISES 5-YR ANALYSIS

COMPARE PIRAMAL ENTERPRISES WITH

MARKET STATS